Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

References 134

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.
   The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer · 2015

   No notice
10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

20. 20.
    B7-H1 Expression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells · 2013

    No notice
21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

41. 41.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

42. 42.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

43. 43.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

44. 44.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

46. 46.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

47. 47.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

49. 49.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

50. 50.
    Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma · 2015

    No notice
51. 51.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

52. 52.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

53. 53.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

54. 54.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

55. 55.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

56. 56.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

57. 57.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

58. 58.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

59. 59.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

60. 60.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

61. 61.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

62. 62.
    Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity · 2016

    No notice
63. 63.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

64. 64.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

65. 65.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

66. 66.
    Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy · 2016

    No notice
67. 67.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

68. 68.
    T cells in multiple myeloma display features of exhaustion and senescence at the tumor site · 2016

    No notice
69. 69.
    RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers · 2016

    No notice
70. 70.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

71. 71.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

72. 72.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

73. 73.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

74. 74.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

75. 75.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

76. 76.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

77. 77.
    An unexpected N-terminal loop in PD-1 dominates binding by nivolumab · 2017

    No notice
78. 78.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

79. 79.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

80. 80.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

81. 81.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

82. 82.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

83. 83.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

84. 84.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

85. 85.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

86. 86.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

87. 87.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

88. 88.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

89. 89.
    Prognostic significance of PD-L1 in solid tumor · 2017

    No notice
90. 90.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

91. 91.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

92. 92.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

93. 93.
    HDAC inhibitors enhance the immunotherapy response of melanoma cells · 2017

    No notice
94. 94.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

95. 95.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

96. 96.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

97. 97.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

98. 98.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

99. 99.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

100. 100.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

101. 101.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

102. 102.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

103. 103.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

104. 104.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

105. 105.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

106. 106.
     High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma · 2017

     No notice
107. 107.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

108. 108.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

109. 109.
     MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells · 2017

     No notice
110. 110.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

111. 111.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

112. 112.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

113. 113.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

114. 114.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

115. 115.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

116. 116.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

117. 117.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

118. 118.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

119. 119.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

120. 120.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

121. 121.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

122. 122.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

123. 123.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

124. 124.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

125. 125.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

126. 126.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

127. 127.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

128. 128.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

129. 129.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

130. 130.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

131. 131.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

132. 132.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

133. 133.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

134. 134.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

Cited by papers we hold 6

• Peptides as multifunctional players in cancer therapy · 2023
  No notice
• The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers · 2022
  No notice
• PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy · 2021
  No notice
• Role of CD47 in Hematological Malignancies · 2020
  No notice
• Role of HDACs in normal and malignant hematopoiesis · 2020
  Corrected
• Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors · 2018
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.